Mode
Text Size
Log in / Sign up

Neovascular glaucoma

Part of Glaucoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for neovascular glaucoma

6 trials tracked for neovascular glaucoma: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 15 citations.

6Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 1 Other / NA 2
  1. Phase 3 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied Completed · 15 cited
  2. Phase 3 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Completed · 15 cited
  3. Phase 3 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed
  4. Phase 2 Ahmed Glaucoma Valve Surgery With Mitomycin-C Completed
  5. N/A Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma Completed
  6. N/A Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Neovascular glaucoma: what the trials found

Aflibercept has been evaluated in Phase 3 trials for the management of neovascular glaucoma. In one study, Aflibercept administration resulted in a significant reduction in intraocular pressure (IOP) from baseline to week 1 (-8.3; p=0.0004).

In another Phase 3 trial involving Aflibercept, results for IOP change at week 1 were -8.5 and -4.9 (p=0.0644). Regarding the Neovascularization of the Iris (NVI) grade, these trials reported improvement rates of 13% and 70.4% respectively.

Ranibizumab was also evaluated in a Phase 3 trial for this condition.

Recent results — preliminary, needs further review

  • Mitomycin-C was assessed in a Phase 2 trial (not yet corroborated).
  • MicroPulse® P3 Glaucoma Device (MP3) showed Cup-to-disc Ratio (CDR) and OCT-assessed CDR of 0.82 (not yet corroborated).
  • Aflibercept was evaluated in a small study showing specific baseline and week 52 IOP measurements (not yet corroborated).

For the clinician treating this condition

  • Aflibercept is associated with significant reductions in intraocular pressure (IOP) at one week post-treatment.
  • Clinical evidence for Aflibercept shows varying rates of improvement in Neovascularization of the Iris (NVI) grade between different Phase 3 studies.
  • Ranibizumab has been investigated as a treatment option in Phase 3 clinical trials.

AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Glaucoma

Related studies from across the Glaucoma family.

Peripheral visual field loss correlates with poorer balance performance and sensory strategies in patients with glaucoma
Ophthalmology Meta-analysis
Peripheral visual field loss correlates with poorer balance performance and sensory strategies in patients with glaucoma Peripheral Vision Loss Linked to Poorer Balance in Glaucoma Patients
This systematic review and meta-analysis of 2456 participants found that individuals with peripheral visual field loss (PVFL) exhibit worse …
People with limited peripheral vision, such as those with glaucoma, may experience significant balance issues due to changes in how they pro…
Hydrogels overcome physiological barriers to improve drug delivery and tissue repair in anterior segment diseases
Ophthalmology Sys. Review
Hydrogels overcome physiological barriers to improve drug delivery and tissue repair in anterior segment diseases Hydrogels Improve Drug Delivery for Various Eye Conditions
This systematic review evaluates hydrogel platforms including adhesive drops, thermosensitive gels, and drug-eluting lenses compared to conv…
New hydrogel technologies may overcome the limitations of standard eye drops to provide longer-lasting treatment for conditions like glaucom…
Phacoemulsification addition to ab-interno canaloplasty does not significantly improve intraocular pressure or medication reduction
Ophthalmology Meta-analysis
Phacoemulsification addition to ab-interno canaloplasty does not significantly improve intraocular pressure or medication reduction Adding cataract surgery to canaloplasty does not change glaucoma results
This meta-analysis of 663 eyes evaluated the impact of combining phacoemulsification with ab-interno canaloplasty (ABiC) for open-angle glau…
Combining cataract surgery with a specific eye procedure called canaloplasty does not provide extra benefits for lowering pressure in glauco…
Comparative Efficacy and Safety of Preservative-Free versus Preserved Latanoprost for Glaucoma
Ophthalmology Meta-analysis
Comparative Efficacy and Safety of Preservative-Free versus Preserved Latanoprost for Glaucoma Preservative-Free Latanoprost Cuts Eye Redness Risk
A meta-analysis of 1880 eyes compares preservative-free latanoprost to preserved versions, evaluating IOP reduction and ocular surface safet…
A new analysis finds preservative-free latanoprost lowers eye redness risk by 34% while matching standard drops' pressure control after 4 we…
Brinzolamide/timolol provides greater morning IOP reduction and lower eye irritation than dorzolamide/timolol
Ophthalmology Meta-analysis
Brinzolamide/timolol provides greater morning IOP reduction and lower eye irritation than dorzolamide/timolol Brinzolamide and Timolol Show Better Morning Pressure Reduction for Glaucoma
This systematic review and meta-analysis of 1885 patients found that brinzolamide/timolol (BT) achieved a statistically greater reduction in…
A new analysis shows that the combination of brinzolamide and timolol may lower morning eye pressure more than dorzolamide and timolol.
Slow-coagulation transscleral cyclophotocoagulation provides greater IOP reduction than micropulse transscleral cyclophotocoagulation in glaucoma
Ophthalmology Meta-analysis
Slow-coagulation transscleral cyclophotocoagulation provides greater IOP reduction than micropulse transscleral cyclophotocoagulation in glaucoma Slow-coagulation Treatment Shows More IOP Reduction for Glaucoma
This systematic review and meta-analysis of 992 patients compared three cyclophotocoagulation modalities for glaucoma. The analysis found th…
A new review suggests slow-coagulation treatment may lower eye pressure more effectively than micropulse methods for patients with glaucoma.
C-reactive protein levels significantly higher in normal tension glaucoma patients
Ophthalmology Meta-analysis
C-reactive protein levels significantly higher in normal tension glaucoma patients Inflammation marker linked to one type of glaucoma
This meta-analysis of 766 patients found significantly higher CRP levels in normal tension glaucoma (NTG) compared to controls, but no signi…
People with normal tension glaucoma had higher CRP levels, a sign of inflammation, than those without glaucoma. The finding may help identif…
Melbourne Rapid Fields provide comparable diagnostic information to Humphrey Field Analyzer for glaucoma perimetry
Ophthalmology Meta-analysis
Melbourne Rapid Fields provide comparable diagnostic information to Humphrey Field Analyzer for glaucoma perimetry Melbourne Rapid Fields Provide Comparable Data to Humphrey Field Analyzer
This meta-analysis of 9 studies involving 777 eyes compares Melbourne Rapid Fields (MRF) and Humphrey Field Analyzer (HFA) performance. The …
A new analysis shows the Melbourne Rapid Fields test provides similar glaucoma data to standard tests while offering a faster testing time.
XEN-only surgery achieves lower postoperative IOP than trabeculectomy but has higher bleb needling rates
Ophthalmology Meta-analysis
XEN-only surgery achieves lower postoperative IOP than trabeculectomy but has higher bleb needling rates New analysis compares surgical options for open angle glaucoma
This systematic review and meta-analysis of 56 studies compared XEN-only, Phaco-XEN, and trabeculectomy for open-angle glaucoma. Findings in…
Two different surgery types for glaucoma both lower eye pressure, but one method may lead to fewer complications during follow-up care.
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
Drug Pipeline Meta-analysis
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis New analysis shows GLP-1 drugs do not raise eye disease risk for diabetes patients
This systematic review and meta-analysis of 28 observational studies found that GLP-1 receptor agonists did not increase the risk of NAION, …
A large review of 28 studies found that diabetes drugs called GLP-1 receptor agonists do not increase the risk of eye problems like glaucoma…
Metformin use linked to modest glaucoma risk reduction in diabetic patients
Ophthalmology Meta-analysis
Metformin use linked to modest glaucoma risk reduction in diabetic patients Metformin use linked to lower glaucoma risk in people with diabetes
A large meta-analysis of diabetic patients found metformin use associated with a modest reduction in glaucoma incidence, though evidence cer…
A massive review of over 1.2 million patients suggests metformin might lower the chance of developing glaucoma compared to other diabetes dr…
Netarsudil plus latanoprost cuts diurnal IOP 2.36 mmHg vs latanoprost alone in Japanese glaucoma
Ophthalmology RCT
Netarsudil plus latanoprost cuts diurnal IOP 2.36 mmHg vs latanoprost alone in Japanese glaucoma Adding netarsudil to latanoprost lowers eye pressure faster in Japanese patients with glaucoma
This Phase III randomized controlled trial in 246 Japanese participants with primary open-angle glaucoma or ocular hypertension found that n…
Japanese patients with glaucoma saw lower eye pressure when adding netarsudil to their current latanoprost drops compared to a placebo plus …